Durvalumab with or without Olaparib in Patients with Endometrial Cancers Regulatory Post marketing Surveillance

Trial Identifier:	D9102R00001
Sponsor:	AstraZeneca
Start Date:	September 2025
Primary Completion Date:	June 2029
Study Completion Date:	June 2029
Condition:	Endometriosis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
South Korea	Seoul, South Korea

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.